[go: up one dir, main page]

SE8304393D0 - Controlled release naproxen and naproxen sodium tablets - Google Patents

Controlled release naproxen and naproxen sodium tablets

Info

Publication number
SE8304393D0
SE8304393D0 SE8304393A SE8304393A SE8304393D0 SE 8304393 D0 SE8304393 D0 SE 8304393D0 SE 8304393 A SE8304393 A SE 8304393A SE 8304393 A SE8304393 A SE 8304393A SE 8304393 D0 SE8304393 D0 SE 8304393D0
Authority
SE
Sweden
Prior art keywords
naproxen
controlled release
weight percent
sodium tablets
naproxen sodium
Prior art date
Application number
SE8304393A
Other languages
English (en)
Other versions
SE8304393L (sv
SE454565B (sv
Inventor
C H Hsiao
J S Kent
Original Assignee
Syntex Pharma Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24004892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8304393(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex Pharma Int filed Critical Syntex Pharma Int
Publication of SE8304393D0 publication Critical patent/SE8304393D0/sv
Publication of SE8304393L publication Critical patent/SE8304393L/sv
Publication of SE454565B publication Critical patent/SE454565B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SE8304393A 1983-06-14 1983-08-12 Tablett av controlled release-typ innehallande naproxen eller naproxennatrium SE454565B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/504,112 US4571333A (en) 1983-06-14 1983-06-14 Controlled release naproxen and naproxen sodium tablets

Publications (3)

Publication Number Publication Date
SE8304393D0 true SE8304393D0 (sv) 1983-08-12
SE8304393L SE8304393L (sv) 1984-12-15
SE454565B SE454565B (sv) 1988-05-16

Family

ID=24004892

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8304393A SE454565B (sv) 1983-06-14 1983-08-12 Tablett av controlled release-typ innehallande naproxen eller naproxennatrium

Country Status (24)

Country Link
US (2) US4571333A (sv)
AT (1) AT389225B (sv)
AU (1) AU552080B2 (sv)
BE (1) BE899885A (sv)
CA (1) CA1204671A (sv)
CH (1) CH643455A5 (sv)
DE (1) DE3329265A1 (sv)
DK (1) DK162814C (sv)
FI (1) FI83037C (sv)
FR (1) FR2547498B1 (sv)
GB (1) GB2141338B (sv)
HK (1) HK95590A (sv)
IE (1) IE55585B1 (sv)
IL (1) IL69371A0 (sv)
IT (1) IT1200967B (sv)
LU (1) LU84962A1 (sv)
MY (1) MY100439A (sv)
NL (1) NL191669C (sv)
NO (1) NO167001C (sv)
NZ (1) NZ204708A (sv)
PH (1) PH17827A (sv)
SE (1) SE454565B (sv)
SG (1) SG80990G (sv)
ZA (1) ZA835591B (sv)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061897A (en) * 1976-01-23 1977-12-06 Audrae Thykeson Heating pad
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US5527545A (en) * 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5198227A (en) * 1990-01-22 1993-03-30 Mcneil-Ppc, Inc. Dual subcoated simulated capsule medicament
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
US5225201A (en) * 1991-08-23 1993-07-06 Minnesota Mining And Manufacturing Company Salsalate tablet
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140183C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140172C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Ibuprofen enthaltendes Arzneimittel
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DK0557244T3 (da) * 1992-02-17 1996-04-01 Siegfried Ag Pharma Dosisformer med forlænget afgivelse af aktivt stof
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
WO1993017673A1 (en) * 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
PT661045E (pt) * 1992-09-18 2002-11-29 Yamanouchi Pharma Co Ltd Preparacao em hidrogel de libertacao prolongada
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US5792886A (en) * 1997-01-08 1998-08-11 Albemarle Corporation Production of racemic 2-(6-methoxy-2-naphthyl) propionic acid of precursors thereof
US6080888A (en) * 1997-01-08 2000-06-27 Albemarle Corporation Preparation of olefinic compounds and carboxylic derivatives thereof
US6096920A (en) * 1997-01-08 2000-08-01 Albemarle Corporation Preparation of carboxylic compounds and their derivatives
US5859292A (en) * 1997-12-11 1999-01-12 Albemarle Corporation Preparation of high purity sodium (S)-2(6-methoxy-2-naphthyl)propionate
US5874614A (en) * 1997-12-11 1999-02-23 Albemarle Corporation Sodium (S)-2-(6-methoxy-2-naphthyl)propionate monohydrate
US7235258B1 (en) * 1999-10-19 2007-06-26 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating CNS-mediated disorders
US6448410B1 (en) 2000-01-18 2002-09-10 Albemarle Corporation Production of compacted biocidal agent from particulate biocidal agent without using a binder
US20050049420A1 (en) * 2000-01-18 2005-03-03 Elnagar Hassan Y. Process for producing N-halogenated organic compounds
US6680070B1 (en) 2000-01-18 2004-01-20 Albemarle Corporation Particulate blends and compacted products formed therefrom, and the preparation thereof
US7579018B2 (en) * 2000-01-18 2009-08-25 Albemarle Corporation Microbiological control in aqueous systems
US7371397B2 (en) * 2000-01-18 2008-05-13 Albemarle Corporation Methods for microbiological control in aqueous systems
US6638959B2 (en) 2000-01-18 2003-10-28 Albemarle Corporation Microbiological control in aqueous systems
US6565868B1 (en) 2000-01-18 2003-05-20 Albemarle Corporation Methods for microbiological control in aqueous systems
US7999118B2 (en) * 2000-01-18 2011-08-16 Albemarle Corporation Process for producing N-halogenated hydantoins
US6508954B1 (en) 2000-01-18 2003-01-21 Albemarle Corporation 1,3-dibromo-5,5-dimethylhydantoin of enhanced properties
US6495698B1 (en) 2000-01-18 2002-12-17 Albemarle Corporation Binder-free compacted forms of 1,3-dihalo-5,5-dimethylhydantoins
US6809205B1 (en) 2000-01-18 2004-10-26 Albemarle Corporation Process for producing N-halogenated organic compounds
US6919364B2 (en) * 2001-06-28 2005-07-19 Solution Biosciences, Inc. Microbiological control in animal processing
US6986910B2 (en) * 2001-06-28 2006-01-17 Albemarle Corporation Microbiological control in poultry processing
WO2003011033A1 (en) * 2001-06-28 2003-02-13 Solution Biosciences, Inc. Microbiological control in animal processing
EA200400343A1 (ru) * 2001-08-29 2004-08-26 Рэнбакси Лабораториз Лимитед Композиция с контролируемым высвобождением кларитромицина или тинидазола
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
JP4709486B2 (ja) * 2001-10-09 2011-06-22 アルベマール・コーポレーシヨン 産業用水システム中のバイオフィルムの抑制
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US20040010024A1 (en) * 2002-07-10 2004-01-15 Howarth Jonathan N. Particulate blends and compacted products formed therefrom, and the preparation thereof
US6965035B1 (en) 2002-07-25 2005-11-15 Albemarle Corp Compacted forms of halogenated hydantoins
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040228918A1 (en) * 2003-01-02 2004-11-18 Chih-Ming Chen Granule modulating hydrogel system
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US7901276B2 (en) * 2003-06-24 2011-03-08 Albemarle Corporation Microbiocidal control in the processing of meat-producing four-legged animals
US20040265446A1 (en) * 2003-06-24 2004-12-30 Mcnaughton James L. Microbiocidal control in the processing of poultry
US20040265445A1 (en) * 2003-06-24 2004-12-30 Liimatta Eric W. Microbiocidal control in the processing of poultry
US20070092566A1 (en) * 2003-08-04 2007-04-26 Ryouichi Hoshino Oral sustained-release tablet
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
AU2004326202B2 (en) * 2004-12-23 2011-11-10 Albemarle Corporation Microbiocidal control in the processing of meat-producing four-legged animals
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP1959735A1 (en) * 2005-12-01 2008-08-27 Solution Biosciences, Inc. Microbiocidal control in the processing of meat-producing four-legged animals
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US20090087490A1 (en) * 2007-06-08 2009-04-02 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
EP2590636A1 (en) 2010-07-06 2013-05-15 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
US9415048B2 (en) * 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20120244218A1 (en) 2011-03-25 2012-09-27 Durkee Shane E Calcium supplement
CN106880614A (zh) * 2017-04-06 2017-06-23 地奥集团成都药业股份有限公司 一种萘普生缓释片及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
DE1228029C2 (de) * 1964-05-09 1973-05-17 Merck Ag E Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
FR2146564A5 (sv) * 1971-07-19 1973-03-02 Peugeot & Renault
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets

Also Published As

Publication number Publication date
SG80990G (en) 1990-11-23
ZA835591B (en) 1985-03-27
CH643455A5 (de) 1984-06-15
NL191669C (nl) 1996-02-05
NO842362L (no) 1984-12-17
IL69371A0 (en) 1983-11-30
DE3329265C2 (sv) 1991-04-11
FI842400L (fi) 1984-12-15
PH17827A (en) 1985-01-07
HK95590A (en) 1990-11-23
IT8367870A0 (it) 1983-08-12
SE8304393L (sv) 1984-12-15
NL191669B (nl) 1995-10-02
DE3329265A1 (de) 1984-12-20
NO167001C (no) 1991-09-25
DK162814C (da) 1992-05-04
FI83037B (fi) 1991-02-15
US4803079A (en) 1989-02-07
IE831799L (en) 1984-12-14
ATA191084A (de) 1989-04-15
NO167001B (no) 1991-06-17
US4571333A (en) 1986-02-18
AT389225B (de) 1989-11-10
SE454565B (sv) 1988-05-16
DK553683A (da) 1984-12-15
AU1801183A (en) 1984-12-20
IT1200967B (it) 1989-01-27
GB2141338A (en) 1984-12-19
FR2547498A1 (fr) 1984-12-21
BE899885A (fr) 1984-12-12
LU84962A1 (de) 1983-12-28
GB2141338B (en) 1988-06-02
DK553683D0 (da) 1983-12-01
IE55585B1 (en) 1990-11-07
NL8302842A (nl) 1985-01-02
FI842400A0 (fi) 1984-06-13
GB8321757D0 (en) 1983-09-14
MY100439A (en) 1990-09-29
DK162814B (da) 1991-12-16
NZ204708A (en) 1984-12-14
FI83037C (sv) 1991-05-27
CA1204671A (en) 1986-05-20
FR2547498B1 (fr) 1986-06-13
AU552080B2 (en) 1986-05-22

Similar Documents

Publication Publication Date Title
SE8304393D0 (sv) Controlled release naproxen and naproxen sodium tablets
Lanza A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects
ATE213629T1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
ES2090368T3 (es) Composiciones farmaceuticas que contienen glucosaminoglicanos absorbibles por via oral.
DK0797435T3 (da) Matrice til kontrolleret frigivelse af lægemidler
ES8402155A1 (es) Un metodo para producir formas posologicas unitarias solidas que al administrarse siguen una pauta de liberacion regular y prolongada.
ATE189400T1 (de) Knochenwachstumsfördernde zusammensetzung
MY100721A (en) Therapeutic agent.
RU2000131897A (ru) Пероральная дозировочная композиция пролонгированного действия
NO20053106L (no) Oral, analgesisk doseringsform med forlenget frigivelse.
IT1211484B (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
KR850700212A (ko) 서방성 약제학적 캼셀제
FR2735369B1 (fr) Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
CO4940406A1 (es) Composiciones de paracetamol de accion rapida
DE60006362D1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
EP0302714A3 (en) Pharmaceutical composition for treatment of bone-wasting diseases
RU93004785A (ru) Твердые капсулы окфосфата цитарабина
CA2123332A1 (en) Controlled Release Formulation of Diltiazem Hydrochloride
RU97119670A (ru) Способ профилактики иксодовых клещевых боррелиозов
RU96113328A (ru) Способ торможения фиброзообразования
IT1265224B1 (it) Composizioni farmaceutiche per uso orale per il trattamento delle manifestazioni ulcerose gastro-duodenali ed esofagee
NO964775L (no) Fast farmasöytisk adenosinholdig preparat
RU97118477A (ru) Применение ралоксифена или его фармацевтически приемлемой соли в профилактике рака молочной железы

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8304393-5

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8304393-5

Format of ref document f/p: F